Cargando…

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort

BACKGROUND: Age-adjusted lymphoma incidence rates continue to rise in France since the early 80’s, although rates have slowed since 2010 and vary across subtypes. Recent improvements in patient survival in major lymphoma subtypes at population level raise new questions about patient outcomes (i.e. q...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghesquières, Hervé, Rossi, Cédric, Cherblanc, Fanny, Le Guyader-Peyrou, Sandra, Bijou, Fontanet, Sujobert, Pierre, Fabbro-Peray, Pascale, Bernier, Adeline, Belot, Aurélien, Chartier, Loic, Fornecker, Luc-Matthieu, Baldi, Isabelle, Bouabdallah, Krimo, Laurent, Camille, Oberic, Lucie, Morineau, Nadine, Le Gouill, Steven, Morschhauser, Franck, Haioun, Corinne, Damaj, Gandhi, Guidez, Stéphanie, Labouré, Gaëlle, Fitoussi, Olivier, Lebras, Laure, Gressin, Rémy, Salles, Gilles, Ysebaert, Loïc, Monnereau, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927409/
https://www.ncbi.nlm.nih.gov/pubmed/33653294
http://dx.doi.org/10.1186/s12889-021-10433-4
_version_ 1783659662856421376
author Ghesquières, Hervé
Rossi, Cédric
Cherblanc, Fanny
Le Guyader-Peyrou, Sandra
Bijou, Fontanet
Sujobert, Pierre
Fabbro-Peray, Pascale
Bernier, Adeline
Belot, Aurélien
Chartier, Loic
Fornecker, Luc-Matthieu
Baldi, Isabelle
Bouabdallah, Krimo
Laurent, Camille
Oberic, Lucie
Morineau, Nadine
Le Gouill, Steven
Morschhauser, Franck
Haioun, Corinne
Damaj, Gandhi
Guidez, Stéphanie
Labouré, Gaëlle
Fitoussi, Olivier
Lebras, Laure
Gressin, Rémy
Salles, Gilles
Ysebaert, Loïc
Monnereau, Alain
author_facet Ghesquières, Hervé
Rossi, Cédric
Cherblanc, Fanny
Le Guyader-Peyrou, Sandra
Bijou, Fontanet
Sujobert, Pierre
Fabbro-Peray, Pascale
Bernier, Adeline
Belot, Aurélien
Chartier, Loic
Fornecker, Luc-Matthieu
Baldi, Isabelle
Bouabdallah, Krimo
Laurent, Camille
Oberic, Lucie
Morineau, Nadine
Le Gouill, Steven
Morschhauser, Franck
Haioun, Corinne
Damaj, Gandhi
Guidez, Stéphanie
Labouré, Gaëlle
Fitoussi, Olivier
Lebras, Laure
Gressin, Rémy
Salles, Gilles
Ysebaert, Loïc
Monnereau, Alain
author_sort Ghesquières, Hervé
collection PubMed
description BACKGROUND: Age-adjusted lymphoma incidence rates continue to rise in France since the early 80’s, although rates have slowed since 2010 and vary across subtypes. Recent improvements in patient survival in major lymphoma subtypes at population level raise new questions about patient outcomes (i.e. quality of life, long-term sequelae). Epidemiological studies have investigated factors related to lymphoma risk, but few have addressed the extent to which socioeconomic status, social institutional context (i.e. healthcare system), social relationships, environmental context (exposures), individual behaviours (lifestyle) or genetic determinants influence lymphoma outcomes, especially in the general population. Moreover, the knowledge of the disease behaviour mainly obtained from clinical trials data is partly biased because of patient selection. METHODS: The REALYSA (“REal world dAta in LYmphoma and Survival in Adults”) study is a real-life multicentric cohort set up in French areas covered by population-based cancer registries to study the prognostic value of epidemiological, clinical and biological factors with a prospective 9-year follow-up. We aim to include 6000 patients over 4 to 5 years. Adult patients without lymphoma history and newly diagnosed with one of the following 7 lymphoma subtypes (diffuse large B-cell, follicular, marginal zone, mantle cell, Burkitt, Hodgkin, mature T-cell) are invited to participate during a medical consultation with their hematologist. Exclusion criteria are: having already received anti-lymphoma treatment (except pre-phase) and having a documented HIV infection. Patients are treated according to the standard practice in their center. Clinical data, including treatment received, are extracted from patients’ medical records. Patients’ risk factors exposures and other epidemiological data are obtained at baseline by filling out a questionnaire during an interview led by a clinical research assistant. Biological samples are collected at baseline and during treatment. A virtual tumor biobank is constituted for baseline tumor samples. Follow-up data, both clinical and epidemiological, are collected every 6 months in the first 3 years and every year thereafter. DISCUSSION: This cohort constitutes an innovative platform for clinical, biological, epidemiological and socio-economic research projects and provides an opportunity to improve knowledge on factors associated to outcome of lymphoma patients in real life. TRIAL REGISTRATION: 2018-A01332–53, ClinicalTrials.gov identifier: NCT03869619. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-10433-4.
format Online
Article
Text
id pubmed-7927409
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79274092021-03-03 A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort Ghesquières, Hervé Rossi, Cédric Cherblanc, Fanny Le Guyader-Peyrou, Sandra Bijou, Fontanet Sujobert, Pierre Fabbro-Peray, Pascale Bernier, Adeline Belot, Aurélien Chartier, Loic Fornecker, Luc-Matthieu Baldi, Isabelle Bouabdallah, Krimo Laurent, Camille Oberic, Lucie Morineau, Nadine Le Gouill, Steven Morschhauser, Franck Haioun, Corinne Damaj, Gandhi Guidez, Stéphanie Labouré, Gaëlle Fitoussi, Olivier Lebras, Laure Gressin, Rémy Salles, Gilles Ysebaert, Loïc Monnereau, Alain BMC Public Health Study Protocol BACKGROUND: Age-adjusted lymphoma incidence rates continue to rise in France since the early 80’s, although rates have slowed since 2010 and vary across subtypes. Recent improvements in patient survival in major lymphoma subtypes at population level raise new questions about patient outcomes (i.e. quality of life, long-term sequelae). Epidemiological studies have investigated factors related to lymphoma risk, but few have addressed the extent to which socioeconomic status, social institutional context (i.e. healthcare system), social relationships, environmental context (exposures), individual behaviours (lifestyle) or genetic determinants influence lymphoma outcomes, especially in the general population. Moreover, the knowledge of the disease behaviour mainly obtained from clinical trials data is partly biased because of patient selection. METHODS: The REALYSA (“REal world dAta in LYmphoma and Survival in Adults”) study is a real-life multicentric cohort set up in French areas covered by population-based cancer registries to study the prognostic value of epidemiological, clinical and biological factors with a prospective 9-year follow-up. We aim to include 6000 patients over 4 to 5 years. Adult patients without lymphoma history and newly diagnosed with one of the following 7 lymphoma subtypes (diffuse large B-cell, follicular, marginal zone, mantle cell, Burkitt, Hodgkin, mature T-cell) are invited to participate during a medical consultation with their hematologist. Exclusion criteria are: having already received anti-lymphoma treatment (except pre-phase) and having a documented HIV infection. Patients are treated according to the standard practice in their center. Clinical data, including treatment received, are extracted from patients’ medical records. Patients’ risk factors exposures and other epidemiological data are obtained at baseline by filling out a questionnaire during an interview led by a clinical research assistant. Biological samples are collected at baseline and during treatment. A virtual tumor biobank is constituted for baseline tumor samples. Follow-up data, both clinical and epidemiological, are collected every 6 months in the first 3 years and every year thereafter. DISCUSSION: This cohort constitutes an innovative platform for clinical, biological, epidemiological and socio-economic research projects and provides an opportunity to improve knowledge on factors associated to outcome of lymphoma patients in real life. TRIAL REGISTRATION: 2018-A01332–53, ClinicalTrials.gov identifier: NCT03869619. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-10433-4. BioMed Central 2021-03-02 /pmc/articles/PMC7927409/ /pubmed/33653294 http://dx.doi.org/10.1186/s12889-021-10433-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Ghesquières, Hervé
Rossi, Cédric
Cherblanc, Fanny
Le Guyader-Peyrou, Sandra
Bijou, Fontanet
Sujobert, Pierre
Fabbro-Peray, Pascale
Bernier, Adeline
Belot, Aurélien
Chartier, Loic
Fornecker, Luc-Matthieu
Baldi, Isabelle
Bouabdallah, Krimo
Laurent, Camille
Oberic, Lucie
Morineau, Nadine
Le Gouill, Steven
Morschhauser, Franck
Haioun, Corinne
Damaj, Gandhi
Guidez, Stéphanie
Labouré, Gaëlle
Fitoussi, Olivier
Lebras, Laure
Gressin, Rémy
Salles, Gilles
Ysebaert, Loïc
Monnereau, Alain
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
title A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
title_full A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
title_fullStr A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
title_full_unstemmed A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
title_short A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
title_sort french multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “real world data in lymphoma and survival in adults” (realysa) cohort
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927409/
https://www.ncbi.nlm.nih.gov/pubmed/33653294
http://dx.doi.org/10.1186/s12889-021-10433-4
work_keys_str_mv AT ghesquieresherve afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT rossicedric afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT cherblancfanny afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT leguyaderpeyrousandra afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT bijoufontanet afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT sujobertpierre afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT fabbroperaypascale afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT bernieradeline afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT belotaurelien afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT chartierloic afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT forneckerlucmatthieu afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT baldiisabelle afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT bouabdallahkrimo afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT laurentcamille afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT obericlucie afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT morineaunadine afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT legouillsteven afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT morschhauserfranck afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT haiouncorinne afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT damajgandhi afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT guidezstephanie afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT labouregaelle afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT fitoussiolivier afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT lebraslaure afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT gressinremy afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT sallesgilles afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT ysebaertloic afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT monnereaualain afrenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT ghesquieresherve frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT rossicedric frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT cherblancfanny frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT leguyaderpeyrousandra frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT bijoufontanet frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT sujobertpierre frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT fabbroperaypascale frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT bernieradeline frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT belotaurelien frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT chartierloic frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT forneckerlucmatthieu frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT baldiisabelle frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT bouabdallahkrimo frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT laurentcamille frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT obericlucie frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT morineaunadine frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT legouillsteven frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT morschhauserfranck frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT haiouncorinne frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT damajgandhi frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT guidezstephanie frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT labouregaelle frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT fitoussiolivier frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT lebraslaure frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT gressinremy frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT sallesgilles frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT ysebaertloic frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort
AT monnereaualain frenchmulticentricprospectiveprognosticcohortwithepidemiologicalclinicalbiologicalandtreatmentinformationtoimproveknowledgeonlymphomapatientsstudyprotocoloftherealworlddatainlymphomaandsurvivalinadultsrealysacohort